Background: Alpha-1-acid glycoprotein (AAGP) is an acute-phase protein with high affinity for amide local anaesthetics (LAs), and a major determinant of free and potentially toxic concentrations of LAs in plasma. Neonates are known to have lower plasma concentrations of AAGP than adults, and are at risk of developing high free concentrations of LAs. Data regarding AAGP in newborns are so far sparse. The aim of this study was to determine plasma concentrations of AAGP after delivery of preterm and term infants, and to investigate correlations between AAGP and gestational age, birth weight, gender, and mode of delivery. Methods: In this prospective observational study, blood was sampled from umbilical cords of 70 newborn infants born at gestational weeks 27e42 immediately after delivery. Blood samples were subsequently analysed for AAGP plasma concentrations with an immunoturbidimetric assay. Results: We found higher concentrations of AAGP in infants born vaginally compared with those who were delivered by elective Caesarean section [median (inter-quartile range) 0.189 g litre À1 (0.142e0.263 g litre À1 ) vs 0.110 g litre
The administration of local anaesthetics (LAs) by epidural or wound catheter infusion represents valid options to provide good postoperative analgesia after major surgery in both term and preterm newborn infants. 1e5 However, excessive dosage, unintentional intravascular administration, or rapid systemic absorption of LAs may cause serious complications, such as seizures and haemodynamic collapse. 6e8 Relevant safety issues need to be addressed before recommending the widespread use of regional anaesthesia in these patient categories.
LAs have a high affinity for plasma proteins making the free fraction of key concern regarding potential LA systemic toxicity (LAST). Alpha-1-acid glycoprotein (AAGP), an acute-phase protein, is mainly responsible for the plasma binding of LAs. 9 Low concentrations of AAGP are associated with reduced binding of LAs and result in higher free plasma concentrations of LAs that, in turn, will increase the risk for LAST. It has been shown that plasma concentrations of AAGP in newborns are approximately half of adult levels. 10 LAs also bind to albumin and red blood cells. 11 As albumin concentrations also are reduced in newborn and especially preterm infants, it will probably not provide any additional safety regarding LAST. The high haematocrit of newborn infants is only of limited importance. 12 To our knowledge, AAGP concentrations have not been determined in the very preterm population; furthermore, the effect on AAGP concentrations caused by mode of delivery (vaginal delivery vs Caesarean section) remains unexplored. This is useful knowledge to avoid LAST and make dosage suggestion in these patient categories. The aim of this prospective observational study was to determine AAGP plasma concentrations in preterm and term newborns, and whether there was a correlation between AAGP concentrations and gestational age, birth weight, gender, and mode of delivery.
Methods

Study population
Ethical approval for this study (Dnr:2014/64-31/2) was provided by the ethical committee of Karolinska Institutet, Stockholm, Sweden on April 19, 2014. After written parental informed consent, 70 newborn infants were included in the study.
Blood sampling and measurements
Immediately after delivery, 1 ml blood was sampled from the umbilical artery attached to the placenta. The blood was collected in micro-cuvettes (Microvette ® 500 K2-ethylenediaminetetraacetic acid (EDTA) 500 ml; Sarstedt AG and Co., Nü mbrecht, Germany) and sent for further handling in the hospital laboratory. In the laboratory (Karolinska University Hospital, Huddinge, Sweden, accredited in accordance with the International Standard ISO 15189:2012), the micro-cuvettes were centrifuged at 20 C for 10 min using the Sigma 1e14K centrifuge (LABEX Instrument AB, Osterode am Harz, Germany). Plasma AAGP (orosomucoid) was analysed in EDTA plasma with an immunoturbidimetric assay, cobas C system (Roche Diagnostics, Mannheim, Germany). The lower limit of quantification was 0.1 g litre
À1
, defined as three standard deviations above the lowest standard. The total coefficient of variation was 5%.
Investigated parameters
The AAGP concentrations were analysed in relation to gestational age, birth weight, gender, and mode of delivery (vaginal delivery vs Caesarean section).
Statistical analyses
Median values and inter-quartile range (IQR) were used when describing AAGP concentrations. KruskaleWallis test was used to compare concentrations of AAGP between infants born with different modes of delivery. To investigate the correlation between AAGP and gestational age, the Spearman correlation test was used. Statistics were evaluated by GraphPad InStat 3.10 (GraphPad Software, La Jolla, California, USA).
Results
The patient characteristics of the included newborns are presented in Table 1 . Six infants were excluded because of Fig. 2 ). AAGP concentrations were as high as 0.78 and 0.42 g litre À1 in two infants born <220 days of gestation (delivered vaginally and by acute Caesarean section, respectively). The third infant born <220 days of gestation had an AAGP concentration of 0.14 and was delivered vaginally.
Discussion
The acute-phase protein AAGP has a high affinity for amide LAs and is a major determinant of free and potentially toxic concentrations of LAs in plasma. The main finding of our study was that AAGP plasma concentrations in newborn infants are low (approximately 20% of normal adult concentrations) 13 and appear stable at a low concentration during 260 days of gestation. AAGP concentrations were significantly higher in infants born by normal vaginal delivery compared with elective Caesarean section. Among the participants in our study, there were two infants born <220 gestational days who had high concentrations of AAGP presumably as a response to the stress of being born (one being born vaginally and the other by acute Caesarean section). This may indicate that even very preterm infants can increase their AAGP production in response to stress. Preterm and term newborn infants are occasionally subjected to major surgery and need the best possible postoperative analgesia. Morphine and other opioids are frequently used, but their routine use has recently been debated. 14e16 The trend in adult postoperative care is moving away from routine use of opioids for various reasons. 17, 18 Regional anaesthetic techniques are now used in children 2 and can be used even in extremely preterm infants. 19 However, unintentional overdosing, inadvertent intravascular administration, or excessive absorption of LAs from the injection site may cause serious side-effects (e.g. seizures and haemodynamic collapse).
6e8
In earlier studies, we have found acceptable plasma concentrations of LAs regarding the risk of LAST, combined with the lack of observed side-effects both in preterm and term newborn infants. 19 Even so, there are still unresolved safety issues especially in preterm infants. Defining the AAGP plasma concentrations also in the preterm population is of importance, as low concentrations will reduce plasma protein binding, thereby increasing the free and potentially toxic plasma concentration of LAs.
Plasma concentrations of AAGP in preterm and term newborns
Previous studies have shown that AAGP plasma concentrations in infants are lower than in adults, and that AAGP does not reach adult values until 1 yr of age. 10 Our results show that AAGP concentrations appear to remain stable at a low level until 260 days of gestational age when the levels start to rise significantly. One interpretation of this finding is that the hepatic production of AAGP is immature until about 260 days (36 gestational weeks) when the liver enzyme maturation results in increased synthesis of the glycoprotein. Increased plasma concentrations of AAGP are part of the acute-phase-protein response that is triggered by various modes of stress and constitutes one aspect of the innate immune response. It is well known that vaginal delivery is associated with a substantial endocrine stress response that is considerably higher than what is observed in association with elective Caesarean section. 20 It has hitherto been unknown whether the stress of vaginal delivery is substantial enough to trigger an increased production of AAGP. In line with our prediction, AAGP concentrations were significantly higher after normal vaginal and acute Caesarean delivery than after elective Caesarean section. The number of infants in the age range <260 days (27e36 gestational weeks) was too small to allow for a separate post hoc analysis, but a similar pattern was observed also in this patient category.
Study limitations
Despite the fact that all potential mothers gave consent during the inclusion period, the actual number of preterm infants (<37 gestational weeks) was numerically small (n¼14). This is, of course, a limiting factor that precluded a proper subgroup analysis of these subjects concerning the effect by mode of delivery. To analyse the influence of the low levels of AAGP on the in vitro free fraction of LAs would, of course, have provided further data of interest. To determine plasma protein binding properly would need a total plasma volume of approximately 5 ml. Because of high haemoglobin levels at birth, it is not practically possible to harvest the necessary blood volume to allow proper in vitro plasma binding determinations. In vitro studies are also influenced by other various factors (e.g. pH and temperature) 12 that further complicate such studies.
Against this background, we decided to refrain from attempting to do in vitro analyses of plasma protein binding. It should be noted that eight of the AAGP concentration values in the material were slightly below the lower limit of quantification for the instrument used. Seven of these values were immediately below the limit (0.077e0.099).
Implications for dosing of local anaesthetics in newborn infants
The generally adopted guidelines for safe administration of LAs in children recommend a 40% reduction of the initial bolus and a 50% reduction of the maintenance infusion in neonates compared with older children. 21 The variability in our material is substantial. This is mainly caused by the increasing concentrations of AAGP after 260 days of gestational age. However, during the period 220e260 days, the concentrations are reasonably stable at around 0.15 g litre À1 . Thus, an increased awareness for LAST and a further dose reduction (compared with the recommendations mentioned previously) could be used in patients under the gestational age of 260 days (36 weeks). Further reduction of the dose does not appear to be needed down to 220 days (27 weeks) according to our material. Furthermore, when challenged with a neonatal surgical patient, not only pre-and postnatal ages need to be taken into consideration, but also the mode of delivery represents a factor in this context. Thus, slightly higher doses may be possible to use in infants born by normal vaginal delivery and acute Caesarean section than those born via elective Caesarean section. Our results also imply that even preterm infants are able to increase AAGP production in response to stressful events, and thus, should be able to increase their AAGP levels after surgery [e.g. surgical patent ductus arteriosus (PDA) closure].
We are currently looking further into this issue in extremely preterm infants undergoing surgical PDA closure. Better understanding of AAGP plasma concentrations in preterm and term infants will hopefully help to allow the safe use of continuous or intermittent boluses of LAs during the early postoperative period in this specific patient category. Furthermore, clearance of amide LAs is substantially lower in preterm and term infants, which may increase the risk for LAST further during continuous infusion. 22, 23 Thus, the use of the ester LA, chloroprocaine, which is metabolised by plasma esterases and largely independent of liver maturation, has recently been suggested as a safer alternative. 24 It is currently not possible to issue a more precise dosing recommendation based on our findings, but hopefully more studies in the field will lead to that. In conclusion, gestational age and mode of delivery need to be taken into consideration when determining the dosage of LAs in newborn infants.
